Jagdeep T. Podichetty, Sakshi Sardar, Nick Henscheid, Grace V. Lee, J. Rubin Abrams, Wes Anderson, Shu Chin Ma, Klaus Romero
Artificial Intelligence (AI) and Digital Health Technologies (DHTs) are radically transforming drug development. The FDA and EMA have formulated guidance documents for their use in clinical trials. A pressing need exists for a harmonized approach to assess and implement AI and DHT methodologies as Drug Development Tools (DDTs). As a neutral entity leading public-private partnerships, The Critical Path Institute has the competencies and infrastructure to address AI and DHTs’ pivotal roles in drug development.
You can read this publication in its entirety on the ASCPT website here.
